02 May 2019 administrator Uncategorized EBMT 2019 – Preliminary in-human evaluation of a CD19/CD22 dual CAR-T construct for B-NHL On Wednesday 27 March 2019, Oral Session 20 (OS20) took place at the 45th Annual Meeting of the European Society of Blood and Marrow
02 May 2019 administrator Hočkinov limfom, Hronična limfocitna leukemija, Nehočkinski limfom BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL The American Society for Blood and Marrow Transplantation (ASBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), and
15 Mar 2019 administrator Hronična limfocitna leukemija Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixedduration venetoclax-rituximab compared with
04 Dec 2018 administrator Nehočkinski limfom Next-generation therapy for follicular lymphoma Morschhauser et al report the safety and efficacy of lenalidomide in combination with obinutuzumab and establish the recommended phase 2
04 Dec 2018 administrator Hočkinov limfom A small change makes a big difference in Hodgkin lymphoma At first glance, it may not seem like much, a post hoc retrospective analysis of outcomes for patients with different levels